Home
1
Products
2
MACS Antibodies - REAfinity, REAlease, and REAdye_lease3
https://www.ancell-bio.com.tw/en/ Ancell Technology Inc.
PRODUCTS
  • MACS® Research Use
  • MACS® Clinical Grade
  • Celetrix Electroporation
  • ZENOGEN PHARMA-Cellbanker®
  • ELGA Labwater
others
Home PRODUCTS MACS® Research Use MACS Antibodies - REAfinity, REAlease, and REAdye_lease
4

MACS Antibodies - REAfinity, REAlease, and REAdye_lease

Official Website Click here

Miltenyi Biotec offers a huge range of fully validated antibodies suitable for multiple applications, such as flow cytometry, microscopy, and functional assays. The MACS® Antibody Portfolio guarantees high performance consistency, with the majority manufactured using our innovative and proprietary recombinant antibody technology for unrivalled lot-to-lot reproducibility and standardization.

1babd05ba2809fb0609852ad4c155308.png

Recombinant antibodies are derived from a defined set of genes, and the production process is highly standardized. This means they are consistent in their structure and performance, leading to high experimental reproducibility. Since the gene sequence of a recombinant antibody is known, it is easy to modify the sequence to improve the properties of the antibody.

ce8447713ef531626b540aef548590e9.jpgFlow cytometry is in their genes

REAfinity Antibodies are recombinant antibodies that provide superior lot-to-lot consistency and purity compared to mouse or rat hybridoma-derived, monoclonal antibodies. They have been recombinantly engineered to produce highly specific antibodies that require no FcR blocking step. Additionally, they all have the same IgG1 isotype, requiring less isotype controls.

0fb329ae6c50399361b47a835dd4825a.jpg

Recombinant antibodies for flow cytometry applications:

  • High purity and lot-to-lot consistency for greater reproducibility

    The manufacturing process of REAfinity Recombinant Antibodies ensures high performance consistency based on the following aspects:
    - They are derived from a defined DNA sequence, which encodes only one type of heavy and light chain, ensuring high antibody purity.
    - Production under biologically and chemically defined, standardized culture conditions in mammalian cells, resulting in high lot-to-lot consistency.
    - Analytical, biochemical, and cell-based testing of every manufactured lot.

    aa7e29153e84723142818d101f77ea31.png
  • Eliminates tedious and costly Fc receptor blocking steps

    All REAfinity Recombinant Antibodies contain a specifically mutated human IgG1 Fc region that abolishes their binding to Fcγ receptors. This allows for background-free analysis and eliminates the need for additional blocking steps such as using a FcR blocking reagent.

    REAfinity_no_background_without_blocking_2500.png

  • One universal isotype control for convenience and cost savings

    All REAfinity Recombinant Antibody clones contain the same specifically mutated human IgG1 sequence as their constant region. This offers the possibility to work with only one type of isotype control, reducing the complexity of experiment planning and saving time.
    Hybridoma-derived monoclonal antibodies on the other hand, are composed of antibody isotypes derived from different species and therefore require multiple isotype controls. This complicates not only the management of reagent inventory, but also panel design when setting up experiments.

    9306b2447f4442691533a376a7497c58.png


  • Optimized for flow cytometry applications

    REAfinity Recombinant Antibodies are designed with flow cytometry in mind. The following properties ensure their superior performance as compared to traditional hybridoma-derived monoclonal antibodies:
    - Greater purity
    - No background signal
    - Highly optimized and standardized fluorochrome conjugation process

    ceaf918493da0e8217e79d552d1142f9.png

REAfinity™ Recombinant Antibodies
Flow cytometry is in their genes

7fa6b94f81255727399932c0d0d915ab.png


b0a634b706b122ab2d219221c15ede8a.png

db285212183905f4356636af2c690271.png

Miltenyi Biotech REAlease® Releasable Antibodies were awarded with the technology prize at the Pharmaceutical Flow Cytometry & Imaging 2018 conference in Stevenage, UK. Delegates of the European Laboratory Research & Innovation Group (ELRIG) nominated our technology, underlining its importance for biotechnology and pharmaceutical research.

The basic principle:

REAlease Releasable Antibodies allow for the removal of any labels from cells after cell sorting in just one simple step.
The technology relies on recombinantly engineered antibody fragments that are, unlike conventional antibodies, characterized by low epitope binding affinities.
A novel covalent conjugation approach allows for multimerization and fluorescent labeling of these antibody fragments. They form the so called REAlease Fluorochrome Complex which facilitates high-avidity cell binding that is comparable to conventional fluorochrome conjugates.
This novel and innovative conjugation chemistry allows for fast removal of the REAlease Fluorochrome Complex from the cell surface by adding the REAlease Release Reagent after cell sorting. This leads to disruption of the complex and thereby results in monomerization of the antibody fragments.
Due to their engineered low binding affinity, they spontaneously dissociate from the cell surface.
As a result, label-free cells can be obtained after cell sorting providing maximal flexibility for a wide range of applications.

ad4ad10ca0c6d3c8f4221b71cee91d53.png

How to get lable-free cell after cell sorting:




REAlease Antibody Technology
Label-free cells after cell sorting for maximal flexibility

5f576dfe4ae3cc6fd0986960e32bcf22.png

 1210672